Consumer and clinician perspectives on personalising breast cancer prevention information

被引:22
|
作者
Keogh, L. A. [1 ]
Steel, E. [1 ]
Weideman, P. [2 ,9 ]
Butow, P. [3 ,4 ]
Collins, I. M. [2 ,5 ]
Emery, J. D. [6 ]
Mann, G. B. [7 ,8 ]
Bickerstaffe, A. [9 ]
Trainer, A. H. [2 ,10 ]
Hopper, L. J. [9 ]
Phillips, K. A. [2 ,9 ,11 ]
机构
[1] Univ Melbourne, Ctr Hlth Equ, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[3] Univ Sydney, Ctr Med Psychol & Evidence Based Decis Making CeM, Sydney, NSW, Australia
[4] Univ Sydney, Psychooncol Cooperat Res Grp PoCoG, Sydney, NSW, Australia
[5] Deakin Univ, Greater Green Triangle Clin Sch, Sch Med, Warrnambool, Australia
[6] Univ Melbourne, Dept Gen Practice, Melbourne, Vic, Australia
[7] Royal Melbourne & Royal Womens Hosp, Breast Serv, Melbourne, Vic, Australia
[8] Univ Melbourne, Dept Surg, Melbourne, Vic, Australia
[9] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia
[10] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[11] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
Breast cancer prevention; Risk management; Online risk assessment; Focus groups; Clinician perspectives; Consumer perspectives; RISK; CARE; SUSCEPTIBILITY; GENOMICS; WOMEN; MODEL;
D O I
10.1016/j.breast.2018.11.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Personalised prevention of breast cancer has focused on women at very high risk, yet most breast cancers occur in women at average, or moderately increased risk ( <= moderate risk). Objectives: To determine; 1) interest of women at <= moderate risk (consumers) in personalised information about breast cancer risk; 2) familial cancer clinicians' (FCCs) perspective on managing women at <= moderate risk, and; 3) both consumers' and FCCs reactions to iPrevent, a personalised breast cancer risk assessment and risk management decision support tool. Methods: Seven focus groups on breast cancer risk were conducted with 49 participants; 27 consumers and 22 FCCs. Data were analysed thematically. Results: Consumers reported some misconceptions, low trust in primary care practitioners for breast cancer prevention advice and frustration that they often lacked tailored advice about breast cancer risk. They expressed interest in receiving personalised risk information using iPrevent. FCCs reported an inadequate workforce to advise women at <= moderate risk and reacted positively to the potential of iPrevent to assist. Conclusions: While highlighting a potential role for iPrevent, several outstanding issues remain. For personalised prevention of breast cancer to extend beyond women at high risk, we must harness women's interest in receiving tailored information about breast cancer prevention and identify a workforce willing to advise women. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:39 / 47
页数:9
相关论文
共 50 条
  • [31] Experiences of and perspectives on genetic testing for breast/ovarian cancer in and outside of the customary clinical setting
    Buckmaster, A. M.
    Gallagher, P.
    PSYCHOLOGY & HEALTH, 2010, 25 (09) : 1041 - 1059
  • [32] Breast cancer genetics and risk assessment: an overview for the clinician
    Larkin, L.
    CLIMACTERIC, 2023, 26 (03) : 229 - 234
  • [33] Clinician perspectives on symptom and quality of life experiences of patients during cancer therapies: Implications for eHealth
    Berry, Donna L.
    Nayak, Manan M.
    Abrahm, Janet L.
    Braun, Ilana
    Rabin, Michael S.
    Cooley, Mary E.
    PSYCHO-ONCOLOGY, 2017, 26 (08) : 1113 - 1119
  • [34] Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention
    Schneeweiss, Andreas
    Lux, Michael P.
    Janni, Wolfgang
    Hartkopf, Andreas D.
    Nabieva, Naiba
    Taran, Florin-Andrei
    Overkamp, Friedrich
    Kolberg, Hans-Christian
    Hadji, Peyman
    Tesch, Hans
    Woeckel, Achim
    Ettl, Johannes
    Lueftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Beckmann, Matthias W.
    Belleville, Erik
    Wallwiener, Diethelm
    Brucker, Sara Y.
    Schuetz, Florian
    Fasching, Peter A.
    Fehm, Tanja N.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2018, 78 (03) : 246 - 259
  • [35] Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)
    Runowicz, Carolyn D.
    Costantino, Joseph P.
    Wickerham, Lawrence
    Cecchini, Reena S.
    Cronin, Walter M.
    Ford, Leslie G.
    Vogel, Victor G.
    Wolmark, Norman
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2011, 205 (06) : 535.e1 - 535.e5
  • [36] New Insights Into the Prevention and Treatment of Familial Breast Cancer
    Euhus, David M.
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 103 (04) : 294 - 298
  • [37] Nutrition in the Prevention of Breast Cancer: A Middle Eastern Perspective
    Naja, Farah
    Nasreddine, Lara
    Awada, Sara
    Ahmad, Raeda El Sayed
    Hwalla, Nahla
    FRONTIERS IN PUBLIC HEALTH, 2019, 7
  • [38] Unmet Need for Clinician Engagement Regarding Financial Toxicity After Diagnosis of Breast Cancer
    Jagsi, Reshma
    Ward, Kevin C.
    Abrahamse, Paul H.
    Wallner, Lauren P.
    Kurian, Allison W.
    Hamilton, Ann S.
    Katz, Steven J.
    Hawley, Sarah T.
    CANCER, 2018, 124 (18) : 3668 - 3676
  • [39] Prevention of breast and ovarian cancer in women with gene mutations
    Tuechler, Anja
    Hahnen, Eric
    Schmutzler, Rita
    Rhiem, Kerstin
    GYNAKOLOGIE, 2023, 56 (12): : 840 - 850
  • [40] The role of breastfeeding in breast cancer prevention: a literature review
    Chen, Yulong
    Jiang, Pengli
    Geng, Yongqin
    FRONTIERS IN ONCOLOGY, 2023, 13